Gmsanjivani LLP

Gmsanjivani LLP is a pharmaceutical exporter based in Mumbai, Maharashtra, India. Established on August 10, 2020, the company operates as a limited liability partnership (LLP) under the Corporate Identification Number (CIN) AAT-2786. The registered office is located at B-410 Western Edge II, Western Express Highway, Borivali East, Mumbai, Maharashtra, 400066. The company is owned by three designated partners: Hitesh Madanlal Jain, Sanjay Sampatraj Parekh, and Bhavesh Prakash Jain. Gmsanjivani LLP specializes in the export of finished pharmaceutical formulations, including tablets, capsules, syrups, and injections, catering to various therapeutic categories.

As of the latest available information, Gmsanjivani LLP does not own or operate any manufacturing facilities. The company focuses on sourcing finished pharmaceutical formulations from third-party manufacturers to meet its export requirements. This strategy allows Gmsanjivani LLP to offer a diverse product portfolio without the capital investment associated with owning manufacturing plants.

The leadership team at Gmsanjivani LLP comprises three designated partners:

• Hitesh Madanlal Jain: Appointed on August 10, 2020, he serves as a designated partner, overseeing the company's strategic direction and operations.

• Sanjay Sampatraj Parekh: Also appointed on August 10, 2020, he holds the position of designated partner, contributing to the company's management and decision-making processes.

• Bhavesh Prakash Jain: Joined as a designated partner on April 1, 2022, he plays a key role in the company's leadership, focusing on business development and strategic initiatives.

Gmsanjivani LLP's export activities are primarily focused on markets in Asia, Africa, and Latin America. The company has established a presence in countries such as Singapore, Taiwan, and Somalia, with significant export volumes reported. For instance, as of February 23, 2026, Gmsanjivani LLP had exported 3,734 shipments to Singapore, 1,458 to Taiwan, and 999 to Somalia. While the company does not publicly disclose specific regulatory filings or approvals in the United States, European Union, United Kingdom, Australia, or Japan, its focus on emerging markets suggests a strategic emphasis on regions with growing pharmaceutical demand.

Gmsanjivani LLP has made significant inroads into emerging markets, particularly in Africa, Latin America, and Southeast Asia. The company's export data indicates substantial shipments to countries such as Singapore, Taiwan, and Somalia, reflecting its commitment to expanding its global footprint. By targeting these regions, Gmsanjivani LLP leverages the increasing demand for affordable and quality pharmaceutical products, positioning itself as a key player in these markets.

Gmsanjivani LLP's geographic strategy is characterized by a strong focus on emerging markets, particularly in Asia, Africa, and Latin America. The company's export data highlights substantial shipments to countries such as Singapore, Taiwan, and Somalia, indicating a strategic emphasis on regions with growing pharmaceutical demand. This approach allows Gmsanjivani LLP to diversify its market presence and mitigate risks associated with overreliance on any single region.

As of the latest available information, Gmsanjivani LLP does not publicly disclose its FDA facility registrations, approved Abbreviated New Drug Applications (ANDAs), Drug Master File (DMF) filings, or inspection history. The company's export activities are primarily focused on markets in Asia, Africa, and Latin America, with significant shipments reported to countries such as Singapore, Taiwan, and Somalia. While the company does not provide specific details regarding its FDA status, its strategic focus on emerging markets suggests a tailored approach to regulatory compliance based on target regions.

Gmsanjivani LLP does not publicly disclose information regarding WHO prequalification, EU Good Manufacturing Practice (GMP) certificates, or European Directorate for the Quality of Medicines & HealthCare (EDQM) status. The company's export activities are primarily concentrated in emerging markets, with substantial shipments to countries such as Singapore, Taiwan, and Somalia. While specific certifications are not disclosed, Gmsanjivani LLP's focus on these regions indicates a strategic emphasis on meeting the regulatory requirements pertinent to its target markets.

Gmsanjivani LLP operates under the regulatory framework of the Central Drugs Standard Control Organisation (CDSCO) in India. The company holds the Import Export Code (IEC) AAVFG4342C, which is required for international trade. Additionally, Gmsanjivani LLP is registered under the Goods and Services Tax (GST) with the number 27AAVFG4342C1ZC, indicating compliance with Indian tax regulations. While specific details regarding CDSCO manufacturing licenses, state drug controller approvals, or export No Objection Certificates (NOCs) are not publicly disclosed, the company's adherence to these regulatory requirements is implied by its operational status and export activities.

As of the latest available information, there are no publicly disclosed records of Form 483 observations, warning letters, or import alerts associated with Gmsanjivani LLP. The company's export activities are primarily focused on markets in Asia, Africa, and Latin America, with significant shipments reported to countries such as Singapore, Taiwan, and Somalia. While specific regulatory actions are not disclosed, the absence of such records suggests a favorable compliance history in its operational regions.

Gmsanjivani LLP operates in a competitive landscape characterized by numerous pharmaceutical exporters targeting emerging markets. While specific competitors are not publicly disclosed, the company's export data indicates significant shipments to countries such as Singapore, Taiwan, and Somalia, suggesting competition with other exporters in these regions. The company's focus on finished pharmaceutical formulations, including tablets, capsules, syrups, and injections, positions it in direct competition with other exporters offering similar products. To maintain a competitive edge, Gmsanjivani LLP emphasizes quality, reliability, and compliance with regulatory standards pertinent to its target markets.

Gmsanjivani LLP differentiates itself through its strategic focus on emerging markets, particularly in Asia, Africa, and Latin America. The company's export data highlights substantial shipments to countries such as Singapore, Taiwan, and Somalia, reflecting its commitment to meeting the growing demand for affordable and quality pharmaceutical products in these regions. Additionally, Gmsanjivani LLP's emphasis on finished pharmaceutical formulations, including tablets, capsules, syrups, and injections, allows it to offer a comprehensive product portfolio tailored to the needs of its diverse clientele.

Gmsanjivani LLP's current strategic direction centers on expanding its presence in emerging markets by leveraging its expertise in exporting finished pharmaceutical formulations. The company's export data indicates significant shipments to countries such as Singapore, Taiwan, and Somalia, underscoring its commitment to these regions. Looking ahead, Gmsanjivani LLP aims to strengthen its market position by enhancing product offerings, ensuring compliance with international regulatory standards, and building long-term partnerships with stakeholders in its target markets.

Gmsanjivani LLP's supplier assessment focuses on sourcing finished pharmaceutical formulations from third-party manufacturers to meet its export requirements. The company's export data indicates substantial shipments to countries such as Singapore, Taiwan, and Somalia, reflecting a consistent and reliable supply chain. While specific details regarding supplier relationships are not publicly disclosed, the company's emphasis on quality, compliance, and timely delivery suggests a robust and dependable supplier network.

Importers considering partnerships with Gmsanjivani LLP should verify the following certifications to ensure compliance with international standards:

• FDA Registration: Confirm the company's registration with the U.S. Food and Drug Administration (FDA) to ensure adherence to U.S. regulatory requirements.

• WHO-GMP Certification: Verify the World Health Organization's Good Manufacturing Practice (GMP) certification to ensure product quality and safety.

• EU GMP Certification: Check for compliance with European Union GMP standards to meet European market requirements.

• ISO Certification: Ensure the company holds relevant International Organization for Standardization (ISO) certifications, indicating adherence to international quality management standards.

To verify these certifications, importers